Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Gross Profit | -2.9M | 21.7% |
| Cost of Revenue | 2.9M | 21.7% |
| Operating expense | 41M | 18.6% |
| Net Income | -94M | 89.9% |
| EBITDA | -95M | 102.2% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 362M | 18.8% |
| Total Liabilities | 239M | 1.1% |
| Total Equity | 123M | 41.4% |
| Shares Outstanding | 238M | 0.3% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | -33M | 32% |
| Cash from investing | 7.7M | 53.7% |
| Cash from financing | 560,000 | 42.9% |
EPS
Financial Highlights for Sana Biotechnology in Q2 '25
Gross Profit stood at -2.9M, marking a 21.7% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 2.9M, a -21.7% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 41M, showing a -18.6% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -94M, showing a -89.9% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -95M, showing a -102.2% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Sana Biotechnology faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. A decline in EBITDA signals potential operational challenges or increased costs.
